Company intelligence / Profile preview

Vitiprints

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Vitiprints' patented print technology is commercially implemented by partners, enabling production of pharmaceuticals and consumer products with reduced packaging, improved shelf-life, and high scalability[1][2][3][7]. No direct clinical results (not a drug sponsor).

Modalities: Device
Industry: Contract Manufacturing Organization

Partnerships

Tetra Bio-Pharma (commercial manufacturing partnership for oral drug CAUMZ™ and HCC011 for cancer pain[1][2])Veganz Group AG (Europe; exclusive licensing for 2D-printed vegan milk alternatives[3])Milkadamia (US; launches 2D-printed flat pack oat milk using Vitiprints tech[7])

Beyond the preview

Go deeper on Vitiprints.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitiprints.

Explore the full profile